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		Severe	Aplastic	Anemia	(SAA)	is	characterized	by	immune-mediated	bone	marrow	hypoplasia	and	pancytopenia	and	can	be	effectively	treated	with	immunosuppressive	therapy	[1],	mainly	based	on	antithymocyte	globulin	(ATG)	and	cyclosporine	or	with	allogeneic	stem	cell	transplantation	[2].	One	third	of	patients	is	refractory	to	immunosuppression,	with	persistent	severe	cytopenia	and	transfusion	requirement	[1].		Eltrombopag	(ELT)	is	an	orally	bioavailable	thrombopoietin	receptor	(TPO-R)	agonist	approved	for	the	treatment	of	aplastic	anemia	after	an	insufficient	response	to	initial	immunosuppressive	therapy.		Eltrombopag	demonstrated	activity	as	single-agent	in	this	patient	population,	allowing	up	to	50%	of	patients	to	recover	blood	counts	and	to	achieve	transfusion	independence	thus	confirming	the	clinical	benefit	of	this	approach	[3,4].		Eltrombopag	has	also	been	combined	to	standard	horse	ATG	plus	cyclosporine	in	first	line,	resulting	in	impressive	overall	response	rate,	about	90%,	and	a	complete	response	rate	of	40%	[5].	Interestingly,	best	results	were	observed	when	all	drugs	were	started	simultaneously	[5].		Eltrombopag	exhibits	several	actions	on	hematopoietic	stem	cells	by	distinct	mechanisms,	the	main	is	related	to	the	binding	of	TPO	receptor	C-MPL,	but	it	is	demonstrated	that	it	activates	other	signaling	pathways	in	megakaryocytes	(MK)	such	as	STAT3,	ERK	and	AKT	[6,7].		Furthermore,	Eltrombopag,	by	binding	the	TPO	receptor	c-MPL,	at	a	position	distinct	from	the	extracellular	binding	site	of	TPO,	bypasses	this	inhibition	induced	by	interferon-γ	(IFN-γ),	a	pro-inflammatory	cytokine,	that	is	implicated	in	human	hematopoietic	stem	and	progenitor	cell	depletion	in	immune-mediated	bone	marrow	failure	syndromes	[8].		It	was	shown	that	Eltrombopag,	besides	the	known	activity	on	the	TPO	receptor	also	decreases	labile	iron	within	the	cells	[9,10].	Eltrombopag	chelates	both	extra	and	intra	cellular	calcium	and	iron	and	can	shuttle	iron	out	of	cells.	The	iron	chelating	action	of	eltrombopag	causes	anti-proliferative	effects	on	leukemic	cells	lines	[11].	The	chelation	property	can	partially	explain	the	differences	observed	between	eltrombopag	and	other	TPO	mimetic	drugs.		We	report	here	a	case	of	a	patient	affected	by	SAA	who	obtained	complete	hematological	response	when	the	irin	chelator	deferasirox	was	added	to	eltrombopag	therapy.		
Clinical	case	A	female	patient,	67	yrs	old,	was	diagnosed	with	SAA	in	June	2015.	Her	blood	count	was:	white	blood	cells	(WBC)	2.14 × 109/L,	neutrophils	0.4 × 109/L,	Hb	9 gr/dL,	reticulocytes	20 × 109/L,	platelets	(PLT)	7 × 109/L,	serum	ferritin	was	388 ng/mL.	Virus	infections	by	Hepatitis	B	(HBV)	and	C	(HCV),	Ebstein	Barr	(EBV),	Cytomegalovirus	(CMV),	Parvovirus	and	Human	Immunodeficiency	Virus	(HIV)	were	excluded.	Anti	nuclear	antibodies	and	anti	double	strand	DNA	were	negative.	Bone	marrow	aspirate	and	biopsy	showed	a	picture	of	aplastic	anemia	with	an	empty	marrow	and	a	cellularity	less	than	10%.	Cytogenetic	analysis	was	normal.	She	was	treated	with	steroids	and	then	with	cyclosporine	and	four	doses	of	
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thymoglobuline	at	the	dose	of	250 mg/day.	After	4 months	of	immunosuppressive	therapy	the	blood	count	was	unchanged,	the	transfusion	requirement	was	4	platelets	units	and	6	RBC	units/month.	The	serum	ferritin	was	3005 ng/mL,	transferrin	saturation	was	57%.	In	September	2015	she	started	eltrombopag	at	escalating	doses	from	25 mg/day	to	150 mg/day.		In	December	2015,	after	3 months	of	eltrombopag	therapy	the	blood	count	was:	WBC	3.4 × 109/L	neutrophils	0.9 × 109/L,	Hb	8,6 gr/dL,	PLT	6 × 109/L.	PLT	transfusion	requirement	was	stable	and	RBC	transfusion	requirement	was	slightly	reduced	(2	RBC	U/month)	and	the	serum	ferritin	level	was	5506 ng/mL.		In	December	2015	she	started	deferasirox	at	the	dose	of	10 mg/kg/day.	After	1 month	of	deferasirox	and	eltrombopag	therapy	(January	2016)	the	WBC	were	4.5 × 109/L,	neutrophils	2.1 × 109/L,	Hb	9,7 gr/dL,	PLT	22 × 109/L.	She	obtained	transfusion	independence	(Figure	1).	The	Hb	and	platelet	counts	progressively	increased,	in	March	2016	the	WBC	were	4.4 × 109/L,	Hb	11,2 gr/dL,	PLT	29 × 109/L.	In	March	2016	she	suspended	Deferasirox	for	gastrointestinal	intolerance.	After	2 weeks	of	suspension	the	blood	count	was:	WBC	2.8 × 109/L,	neutrophils	0.87 × 109/L,	Hb	8,2 gr/dL,	PLT	12 × 109/L.	She	restarted	transfusions	of	both	RBC	and	PLT.		In	May	2016	she	restarted	deferasirox	at	the	dose	of	10 mg/kg	and	she	obtained	again	RBC	and	PLT	transfusion	independence	and	after	3 weeks	the	blood	count	was:	WBC	3.66 × 109/L,	neutrophils	1.3 × 109/L,	Hb	11,2 gr/dL,	PLT	31 × 109/L.		In	July	2016,	she	discontinued	deferasirox	for	gastrointestinal	intolerance.	After	2 weeks	PLT	and	Hb	decreased	(PLT	13 × 109/L	and	Hb	9 gr/dL).	She	restarted	deferasirox	in	and	the	blood	count	increased	again	and	she	obtained	again	transfusion	independence.		From	July	2016	until	April	2017	the	blood	count	progressively	improved	until	completely	normal	values:	WBC	6.9 × 109/L,	neutrophils	3.1 × 109/L	Hb	13,8	and	PLT	152 × 109/L.		In	July	2017	she	stopped	deferasirox	when	the	serum	ferritin	was	501 ng/mL.	In	2018	she	progressively	reduced	eltrombopag	dose	from	150 mg	to	25 mg/day.		At	the	moment	we	are	writing,	after	40 months	of	eltrombopag	therapy	and	18 months	from	deferasirox	suspension	the	patient	is	in	complete	remission	with	a	normal	blood	count.		She	is	currently	under	eltrombopag	therapy	at	the	dose	of	25 mg	twice	a	week.	Her	blood	count	is:	WBC	6.76 × 109/L,	neutrophils	3.68 × 109/L,	Hb	14,1 gr/dL	and	PLT	201.	×	109/L.		Hematological	responses	in	patients	with	SAA	have	been	reported	during	iron	chelation	therapy	(ICT)	in	many	studies	[12–14].	In	principle,	some	beneficial	effects	of	eltrombopag	on	hematopoiesis	in	aplastic	anemia,	could	also	derive	from	its	property	to	remove	iron.	Many	case	reports	indicate	that	iron	chelation	can	improve	hematopoiesis.	In	2008	Park	and	colleagues	[12]	reported	a	case	of	a	16-yr-old	patient	affected	by	SAA	and	secondary	hemochromatosis	due	to	red	blood	cell	transfusions.	He	was	diagnosed	with	aplastic	anemia	at	11-yr	of	age.	After	five	years	of	transfusions	he	developed	a	dilated	cardiomyopathy,	multiple	endocrine	and	liver	dysfunction,	generalized	bleeding	and	and	skin	pigmentation.	He	started	regular	iron	chelation	therapy	with	deferoxamine,	His	cytopenia	and	organ	dysfunctions	gradually	recovered	until	he	completely	normalized	the	peripheral	blood	cell	
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count.	Following	these	observations	with	deferoxamine	many	cases	have	been	reported	with	oral	iron	chelator	deferasirox.		In	2010	Koh	and	colleagues	[13]	reported	two	children	with	SAA	and	high	transfusion	requirement	with	iron	overload	who	received	iron	chelation	therapy	with	deferasirox.	In	one	of	them	the	restoration	of	trilineage	hematopoiesis	and	consequent	transfusion	independence	was	observed	in	parallel	with	the	reduction	of	serum	ferritin	level.	In	2011	Lee	and	colleagues	[14]	reported	a	case	of	a	child	with	SAA	who,	7 years	after	diagnosis,	was	enrolled	in	a	trial	of	iron	chelation	with	deferasirox.	He	obtained	a	hematological	improvement	and	transfusion	independence.		In	2013	Lee	and	colleagues	[15]	reported	the	post	hoc	analysis	of	the	EPIC	trial,	a	prospective	study	enrolling	patients	with	chronic	anemia	and	iron	overload	due	to	chronic	red	blood	cell	transfusions.		The	analysis	was	conducted	on	a	sub-cohort	of	116	patients	with	aplastic	anemia.	The	hematologic	responses	were	analyzed	in	72	patients	with	evaluable	hematologic	parameters.	Twenty-four	patients	received	deferasirox	without	concomitant	immunosuppressive	treatment.	Partial	hematologic	responses	were	observed	in	11	of	24	(45.8%)	patients;	all	became	transfusion-independent.	One	patient	had	an	additional	platelet	response	and	one	patient	had	an	additional	platelet	and	hemoglobin	response.	The	responses	were	associated	with	a	significantly	reduction	of	serum	ferritin	level.		At	present,	to	the	best	of	our	knowledge,	there	are	no	cases	reported	in	literature	of	patients	with	aplastic	anemia	treated	with	eltrombopag	associated	with	deferasirox.		This	case	strongly	suggests	the	possibility	that	deferasirox	may	improve	eltrombopag	response,	probably	by	removing	toxic	iron.	This	observation	requires	further	investigation	but	it	may	stimulate	clinicians	to	pay	attention	to	this	effect.		 	
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Figure	1.	Hb	and	PLT	count	over	time	during	eltrombopag	(ELT)	and	deferasirox	(DFX)	therapy.		
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